Nivolumab Gets FDA Nod for Bladder Cancer.
The FDA has granted accelerated approval to nivolumab for patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on platinum chemotherapy. This is the second PD-1-targeting agent in less than a year to get the agency's nod for bladder cancer.